menutranslate
young boy holding a gray cat

Share

Clinical Trial of an Experimental Drug for Cat Allergies

This is an offer for cat lovers with swollen eyes and sneezing fits.

Nashville-based BreatheAmerica is seeking participants for a clinical trial of an experimental drug for cat allergies. It’s a monthly immunotherapy treatment, called Cat-PAD, that involves injecting a liquid under the top layer of the cat owner’s skin, where the substance dissolves.

The clinical trial is a Phase 3 study, which means the medicine has already been tested for safety and that researchers seek to measure its effectiveness on a larger group of people.

The treatments are free. At the end of the eight-month study, participants will be reimbursed $50 for the time and travel expense for each checkup they attended. Some participants will receive the drug, while others will receive a placebo.

Eight people have signed up so far in Nashville for the nationwide study. Participants must be between the ages of 12 and 65.

“We are looking for the person who has a cat, knows they are allergic, does not want to get rid of their cat, but wants relief for their symptoms,” said Sonja Plowman, clinical research coordinator of the study for BreatheAmerica.

The study is being conducted out of the company’s Precision Healthcare clinic on Donelson Pike.

“For people who don’t find sufficient relief from or are otherwise burdened by existing treatment options, living with a cat can significantly worsen quality of life,” said Dr David Hagaman, the clinic physician. “Some people ultimately make the emotionally painful decision to give up their cats, depriving themselves or family members from companionship with their beloved pets.”

Current immunotherapy treatments involve weekly injections for several months, sometimes years. Over-the-counter medications are also an option. Researchers want to determine if the Cat-PAD can be a more effective and convenient option.

The study sponsor is England-based Circassia Limited, according to clinicaltrials.gov.